Protein kinase D2 modulates hepatic insulin sensitivity in male mice
Year: 2024
Type: article
Abstract: OBJECTIVES: Protein kinase D (PKD) family is emerging as relevant regulator of metabolic homeostasis. However, the precise role of PKD2 in modulating hepatic insulin signaling has not been fully elucidated and it is the aim of this study. METHODS: mice were fed a chow (CHD) or high fat diet (HFD) and glucose homeostasis and lipid metabolism were investigated. RESULTS: mice, similar steatosis grade was found in both genotypes. CONCLUSIONS: Results herein have unveiled an unknown role of PKD2 in the control of insulin signaling in the liver at the level of IRS1 and point PKD2 as a therapeutic target for hepatic insulin resistance.
Source: Molecular Metabolism
Institutions: Consejo Superior de Investigaciones Científicas, Instituto de Investigaciones Biomédicas Sols-Morreale, Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas, Centro de Investigación Biomédica en Red, Universidad Autónoma de Madrid, University of the Basque Country, Universidad San Pablo CEU, Hospital Universitario Santa Cristina, Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa, Biomedical Research Networking Center on Neurodegenerative Diseases, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Spanish National Centre for Cardiovascular Research, Spanish National Cancer Research Centre
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,870
Funders: Comunidad de Madrid, European Commission, Eusko Jaurlaritza, Ministerio de Ciencia e Innovación, Centro Nacional de Investigaciones Cardiovasculares, Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Instituto de Salud Carlos III, European Regional Development Fund, Agencia Estatal de Investigación, European Social Fund
Awards: G1145146995, G1175115578, G1305536361, G1321103524, G1416831901, G1602493886, G1816341608, G192455069, G2089874362, G2152959462, G2216871892, G2262748287, G2380184687, G24120701, G2601397997, G2672435700, G2704321847, G284951664, G288011245, G2920005363, G294895050, G2992063529, G300979063, G3275705967, G3428307696, G3480869486, G3523405818, G3619008373, G3681454997, Caracterización de los mediadores moleculares clave de la enfermedad hepática grasa metabólica asociada al síndrome de apnea obstructiva del sueño: Implicaciones diagnósticas y terapéuticas, G4033406476, G4042783231, G410571670, G425668148, G451917667, G464105488, G480866104, G489313807, G5080475149, G5195188938, G5199606742, G523076202, G5332219811, G5390950867, G5539308778, G5842359595, G588447059, G5943232429, G5967599077, G6030318399, G6033112984, G6218905885, G6615968613, G7084143925, G7127239378, G7434936867, G7572322741, G7661506209, G7736885172, G7780475403, G8438115295, Dianas terapeuticas y biomarcadores para la medicina de precision en MAFLD (PreMed-MAFLD), G8696694383, G8888022036, G8922119451, Impacto de la proteína morfogenética ósea 12 en la progresión de la enfermedad del hígado graso no alcohólico y en el daño vascular aterosclerótico asociado.
OpenAlex ID: W4403348239